The New AMR Action Fund to Invest in Antibiotic Development

Governments, the health care industry, and the media have all been sounding the alarm about the importance of developing new antibiotics to combat growing antimicrobial resistance (AMR). While there has been some policy movement to address these challenges, the market remains challenging and antibiotic-focused biotechs have few opportunities for partnership and co-investment. To support development and sustain the antibiotic pipeline while the needed market reforms are put in place, over 20 leading pharmaceutical companies have come together to launch the AMR Action Fund, which will invest USD 1 billion to bring 2 to 4 new antibiotics to patients by the end of the decade. Attend to learn how the AMR Action Fund is partnering with biotechs to strengthen and accelerate development of novel antibiotics.